Skip to main content
Premium Trial:

Request an Annual Quote

With Increased Revenues, Decreased Costs, Lynx Considering Various Options

NEW YORK, Aug. 13 (GenomeWeb News) - Lynx Therapeutics of Hayward, Calif., reported increased revenues and slashed its net loss nearly in half, but with $3 million in cash and cash equivalents, including restricted cash, on hand, the company is "considering various other options, including additional equity financing," Kevin Corcoran, the company president and CEO said in a statement today.

 

The Hayward, Calif.-based company reported revenues of $4.6 million for the second quarter ending June 30, compared to $2.9 million for the same quarter a year ago. Net loss was $2.9 million, compared to $5.5 million for the year-ago quarter. The firm reported research and development expenses of $3.2 million for the quarter, compared to $5.4 million a year ago.

 

The company took in $3 million in cash in July from a modification of a collaboration with Takara Bio, and has $1.2 million in accounts receivable, in addition to its cash on hand.

 

The company announced this week that it had retained the Washington, DC-based investment bank Friedman, Billings, and Ramsey as a financial advisor.  

 

 

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.